ArticleOncology letters2025
Blood MALT1 expression levels reflect the lymph node stage and disease-free survival in patients with non-small cell lung cancer.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosa-associated lymphoid tissue lymphoma translocation protein-1 (MALT1) promotes cancer development via both cancer cell-intrinsic and -extrinsic mechanisms, and can regulate cancer immunity and immune escape. Therefore, the present study aimed to assess the expression levels of MALT1 in blood samples and the association with clinical features, treatment options and survival outcomes in patients with non-small cell lung cancer (NSCLC). Peripheral blood mononuclear cells (PBMCs) from a total of 125 patients with resectable NSCLC prior to treatment (neoadjuvant therapy or surgery) were collected. The mRNA expression levels of MALT1 were detected by reverse transcription-quantitative PCR. Furthermore, the PBMC samples from 20 healthy individuals served as the control group. The results showed that MALT1 was upregulated in the blood samples of patients with NSCLC compared with the control group (~3.4:1 fold; P<0.001). Subsequently, for correlation analysis, blood MALT1 expression levels in patients with NSCLC were categorized into four grades according to the quartiles (Q1, Q2, Q3 and Q4). It was indicated that the MALT1 quartile was positively correlated with the tumor-node-metastasis (P=0.036) and N stage (P=0.026), and it had a tendency to be correlated with poor differentiation (P=0.091) and T stage (P=0.058), but this did not reach statistical significance. However, the MALT1 quartile was not associated with neoadjuvant therapy, surgical type or adjuvant therapy. Kaplan-Meier curves demonstrated that the MALT1 quartile was notably associated with shorter disease-free survival (DFS; P=0.009); however, the MALT1 quartile only showed a tendency to be associated with poor overall survival, but this did not reach statistical significance (P=0.118). Subsequent multivariate Cox analysis showed that the MALT1 quartile could independently predict shorter DFS (P=0.016). In conclusion, the present study suggested that blood MALT1 expression levels could potentially predict the stage of lymph node metastasis and DFS in patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.